688073 毕得医药
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)5.0307.4525.7055.26110.793
总资产报酬率 ROA (%)4.1276.1504.8594.5908.941
投入资产回报率 ROIC (%)4.5906.9035.4105.06210.380

边际利润分析
销售毛利率 (%)50.42444.53641.33340.00044.378
营业利润率 (%)20.09014.84313.46011.59820.596
息税前利润/营业总收入 (%)23.13715.87011.4508.83318.457
净利润/营业总收入 (%)15.12911.46210.6569.93217.506

收益指标分析
经营活动净收益/利润总额(%)108.739110.527114.935120.092100.850
价值变动净收益/利润总额(%)2.0525.4153.221-7.042-0.235
营业外收支净额/利润总额(%)-0.164-0.548-0.214-0.5020.022

偿债能力分析
流动比率 (X)7.4626.7436.3888.2239.012
速动比率 (X)4.4283.9284.1895.6806.917
资产负债率 (%)17.18018.73016.16713.47811.998
带息债务/全部投入资本 (%)7.0156.7353.7692.1771.447
股东权益/带息债务 (%)1,301.2421,354.0592,497.9354,387.9926,700.592
股东权益/负债合计 (%)482.055433.895518.561641.976733.488
利息保障倍数 (X)7.51114.329-5.778-3.263-8.610

营运能力分析
应收账款周转天数 (天)69.13364.77674.80367.92765.129
存货周转天数 (天)504.249422.207406.386335.560387.482